The Role of Praziquantel in the Prevention and Treatment of Fibrosis Associated with Schistosomiasis: A Review
Table 3
Clinical efficacy of praziquantel in treatment of patients with schistosomiasis mansoni-induced fibrosis.
Pattern of fibrosis
Treatment regimen
Clinical outcomes of fibrosis
Reference
Hepatic periportal fibrosis
Praziquantel at a total dose of 40 mg/kg
Improvement of periportal thickening/fibrosis in 17.6% of the cohorts, total resolution in 34.7% 26-months post-treatment
60
Hepatic periportal fibrosis
Praziquantel at a total dose of 40 mg/kg
Reduction of hepatic periportal thickening from 46% at baseline to 32% one-year post-treatment and 35% three-year post-treatment
61
Hepatic periportal fibrosis
Praziquantel at a total dose of 50 mg/kg
Significant reduction in the mean values for longitudinal and anteroposterior measurements of liver (left and right lobes) as well as portal vein diameter, a considerable reduction in moderate fibrosis and IL-10 level one-year post-treatment
62
Hepatic periportal fibrosis
Praziquantel at a total dose of 40 mg/kg
Complete reversal of periportal lesions seen in 28.2% subjects; a reduction in periportal thickening followed by a decrease in the size of the left hepatic lobe 3 to 5 years post-treatment
63
Hepatic periportal fibrosis
Praziquantel at a total dose of 40 mg/kg
Improvement in the sonomorphological abnormalities of periportal fibrosis and organomorphometry of livers and spleens one-year post-treatment
